Alyssa Grant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alyssa Grant has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Kednapa Thavorn
The Ottawa Hospital Research Institute, Ottawa, Canada
6 shared publications - Cynthia Gagnon
University of Sherbrooke, Sherbrooke, Canada
3 shared publications - Gerald Pfeffer
University of Calgary
3 shared publications - Hanns Lochmüller
Faculty of Medicine, University of Ottawa, Ottawa, Canada
3 shared publications - Hugh J. McMillan
Division of Neurology, Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
3 shared publications - Ian Curtis Smith
The Ottawa Hospital Research Institute, Ottawa, Canada
3 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Quality of life of individuals with neuromuscular disease: a national cross-sectional survey
- 11 November 2026
- Published by Springer Nature in Health and Quality of Life Outcomes
Open AccessQuality of life of individuals with neuromuscular disease: a national cross-sectional survey
- 11 February 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (5) , 369-382
What Matters Most When Visiting a Rapid Access Addiction Medicine Clinic in Canada for Alcohol Use Care: A National eDelphi Study: Ce qui compte le plus lorsque l'on visite une clinique d'accès rapide au traitement médical de la toxicomanie (RAAM) au Canada pour des soins liés à la consommation d'alcool : une étude eDelphi nationale
Objective: This study explored the importance of various aspects of Rapid Access Addiction Medicine (RAAM) based care for alcohol use health from the perspectives of people across Canada, including those who had and had not accessed RAAM services. Design: Participants ( n = 160) responded to items in rounds of an eDelphi survey, with each progressive round aiming to reach a consensus on the most important components of care at a RAAM clinic. Thirty-eight evidence-informed components were organized into five domains of healthcare accessibility. Ranking was conducted on a 5-point scale, with options ranging from “not at all important” to “critical”. Consensus was defined a priori as 75% or greater ranking agreement. The survey was designed to close after 10 components reached consensus or following four rounds. Results: Eighty-nine participants (mean AUDIT = 13.9, SD = 5.4; mean age = 53.1, SD = 16.1; women = 43%) completed three rounds of the eDelphi. Seven per cent of participants reported having visited a RAAM clinic. The top ten components of care included compassionate care, RAAM team collaboration and effective communication, prompt care, low costs, easy contact, accessible clinic information, strength-focused care, shared decision making and availability of services for individuals across the substance use health spectrum. Conclusions: Findings highlight client-prioritized features of alcohol use health services and offer actionable insights that can help enhance care across care settings. Future research should focus on under-represented populations to ensure that their specific needs are addressed and incorporated into service planning and policy development. Plain Language Summary Title: What Matters Most About Alcohol Use Health Services? Insights from People Across Canada
- 11 February 2026
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 71 (5) , 369-382
What Matters Most When Visiting a Rapid Access Addiction Medicine Clinic in Canada for Alcohol Use Care: A National eDelphi Study: Ce qui compte le plus lorsque l'on visite une clinique d'accès rapide au traitement médical de la toxicomanie (RAAM) au Canada pour des soins liés à la consommation d'alcool : une étude eDelphi nationale
Objective: This study explored the importance of various aspects of Rapid Access Addiction Medicine (RAAM) based care for alcohol use health from the perspectives of people across Canada, including those who had and had not accessed RAAM services. Design: Participants ( n = 160) responded to items in rounds of an eDelphi survey, with each progressive round aiming to reach a consensus on the most important components of care at a RAAM clinic. Thirty-eight evidence-informed components were organized into five domains of healthcare accessibility. Ranking was conducted on a 5-point scale, with options ranging from “not at all important” to “critical”. Consensus was defined a priori as 75% or greater ranking agreement. The survey was designed to close after 10 components reached consensus or following four rounds. Results: Eighty-nine participants (mean AUDIT = 13.9, SD = 5.4; mean age = 53.1, SD = 16.1; women = 43%) completed three rounds of the eDelphi. Seven per cent of participants reported having visited a RAAM clinic. The top ten components of care included compassionate care, RAAM team collaboration and effective communication, prompt care, low costs, easy contact, accessible clinic information, strength-focused care, shared decision making and availability of services for individuals across the substance use health spectrum. Conclusions: Findings highlight client-prioritized features of alcohol use health services and offer actionable insights that can help enhance care across care settings. Future research should focus on under-represented populations to ensure that their specific needs are addressed and incorporated into service planning and policy development. Plain Language Summary Title: What Matters Most About Alcohol Use Health Services? Insights from People Across Canada
- Open Access
- 29 January 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (3) , 423-455
Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations
Background High-risk populations, including transplant recipients, are at increased risk of severe Coronavirus disease 2019 (COVID-19) outcomes. Certain treatments and pre-exposure prophylaxis (PrEP) have been approved to reduce the risk of severe illness. However, data on the cost effectiveness of currently approved COVID-19 therapeutics and preventative treatments are limited for those at high-risk of severe disease. Objective The aim of this study was to systematically review the cost effectiveness of COVID-19 treatments and PrEP in high-risk, immunocompromised, and transplant populations. Methods Electronic databases were searched from inception to September 2025 for studies comparing costs and effectiveness of monoclonal antibodies PrEP or COVID-19 therapeutics in high-risk, immunocompromised or transplant populations. Two reviewers independently screened studies, extracted data, and critically appraised them using the Joanna Briggs Institute checklist for economic evaluations. Cost data are presented in 2025 US dollars. Results Of 8905 studies identified, 60 met inclusion criteria, with seven focused on or including transplant populations. Most studies were cost-utility analyses published between 2020 and 2025. Nirmatrelvir-ritonavir, tixagevimab-cilgavimab, casirivimab-imdevimab, sotrovimab, remdesivir, molnupiravir, and fluvoxamine were compared with no prophylaxis or standard of care. Among transplant populations, the incremental cost-effectiveness ratio (ICER) for tixagevimab-cilgavimab PrEP following vaccination was US$76,024 per quality-adjusted life year (QALY), while ICERs for COVID-19 therapeutics ranged from US$440 to US$126,676 per QALY. Conclusion Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations.
- 29 January 2026
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (3) , 423-455
Open AccessValue of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations
Background High-risk populations, including transplant recipients, are at increased risk of severe Coronavirus disease 2019 (COVID-19) outcomes. Certain treatments and pre-exposure prophylaxis (PrEP) have been approved to reduce the risk of severe illness. However, data on the cost effectiveness of currently approved COVID-19 therapeutics and preventative treatments are limited for those at high-risk of severe disease. Objective The aim of this study was to systematically review the cost effectiveness of COVID-19 treatments and PrEP in high-risk, immunocompromised, and transplant populations. Methods Electronic databases were searched from inception to September 2025 for studies comparing costs and effectiveness of monoclonal antibodies PrEP or COVID-19 therapeutics in high-risk, immunocompromised or transplant populations. Two reviewers independently screened studies, extracted data, and critically appraised them using the Joanna Briggs Institute checklist for economic evaluations. Cost data are presented in 2025 US dollars. Results Of 8905 studies identified, 60 met inclusion criteria, with seven focused on or including transplant populations. Most studies were cost-utility analyses published between 2020 and 2025. Nirmatrelvir-ritonavir, tixagevimab-cilgavimab, casirivimab-imdevimab, sotrovimab, remdesivir, molnupiravir, and fluvoxamine were compared with no prophylaxis or standard of care. Among transplant populations, the incremental cost-effectiveness ratio (ICER) for tixagevimab-cilgavimab PrEP following vaccination was US$76,024 per quality-adjusted life year (QALY), while ICERs for COVID-19 therapeutics ranged from US$440 to US$126,676 per QALY. Conclusion Cost effectiveness varied widely across studies due to differences in variant periods, population risk profiles, model assumptions, and healthcare systems. Future research should integrate variant-specific effectiveness, real-world vaccine responsiveness, long-term COVID-19 outcomes, and adverse events to better inform resource allocation for transplant and other high-risk populations.
- Open Access
- 17 December 2025
- Published by Wiley in Health Expectations
- Vol. 28 (6) , e70529
Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives
Introduction: Neuromuscular diseases (NMDs) impose multifaceted challenges on individuals and their families, often resulting in significant medical and non‐medical expenses. While cost‐of‐illness (COI) studies provide valuable quantitative data, few explore the lived experience of financial strain. This study aims to identify the complex, often hidden, financial impacts experienced by individuals with NMDs and their families. Methods: We conducted a qualitative study involving four virtual semi‐structured focus groups, with 58 participants (76% patients and 24% caregivers). Participants were recruited from Muscular Dystrophy Canada's database and had previously completed the national BIND COI survey. Participants shared firsthand accounts of direct non‐medical costs, psychosocial burdens and opportunity costs, highlighting hidden expenses, substantial out‐of‐pocket costs, and the broader financial and emotional toll on families. Thematic analysis of the transcripts of the discussions was performed using an inductive approach, guided by a rare‐disease‐specific socio‐economic burden framework. Results: Four key themes emerged: informational costs (lack of awareness/support for navigating financial resources), time‐related costs (time spent advocating for supports), opportunity costs (loss of income or career advancement), and costs to independence (emotional toll and out‐of‐pocket costs for assistive devices and home modifications). Conclusion: This study identified four interconnected categories of hidden costs for people with NMDs and their families: informational burdens, administrative and advocacy demands, employment‐related opportunity costs, and reduced independence tied to out‐of‐pocket spending on equipment and home modifications. These findings reveal how financial and emotional pressures accumulate beyond what traditional COI estimates capture. Greater attention to these costs is critical for fostering equitable and sustainable healthcare systems. Patient or Public Contribution: This study was designed and conducted in partnership with individuals living with NMDs and caregivers. Three trained patient and family research partners contributed to the development of the focus group guide and interpretation of results. All participants contributed their lived experiences to inform and validate key findings. Their input was central to the design, analysis and preparation of this manuscript, ensuring alignment with community priorities.
- 17 December 2025
- Published by Wiley in Health Expectations
- Vol. 28 (6) , e70529
Open AccessCounting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives
Introduction: Neuromuscular diseases (NMDs) impose multifaceted challenges on individuals and their families, often resulting in significant medical and non‐medical expenses. While cost‐of‐illness (COI) studies provide valuable quantitative data, few explore the lived experience of financial strain. This study aims to identify the complex, often hidden, financial impacts experienced by individuals with NMDs and their families. Methods: We conducted a qualitative study involving four virtual semi‐structured focus groups, with 58 participants (76% patients and 24% caregivers). Participants were recruited from Muscular Dystrophy Canada's database and had previously completed the national BIND COI survey. Participants shared firsthand accounts of direct non‐medical costs, psychosocial burdens and opportunity costs, highlighting hidden expenses, substantial out‐of‐pocket costs, and the broader financial and emotional toll on families. Thematic analysis of the transcripts of the discussions was performed using an inductive approach, guided by a rare‐disease‐specific socio‐economic burden framework. Results: Four key themes emerged: informational costs (lack of awareness/support for navigating financial resources), time‐related costs (time spent advocating for supports), opportunity costs (loss of income or career advancement), and costs to independence (emotional toll and out‐of‐pocket costs for assistive devices and home modifications). Conclusion: This study identified four interconnected categories of hidden costs for people with NMDs and their families: informational burdens, administrative and advocacy demands, employment‐related opportunity costs, and reduced independence tied to out‐of‐pocket spending on equipment and home modifications. These findings reveal how financial and emotional pressures accumulate beyond what traditional COI estimates capture. Greater attention to these costs is critical for fostering equitable and sustainable healthcare systems. Patient or Public Contribution: This study was designed and conducted in partnership with individuals living with NMDs and caregivers. Three trained patient and family research partners contributed to the development of the focus group guide and interpretation of results. All participants contributed their lived experiences to inform and validate key findings. Their input was central to the design, analysis and preparation of this manuscript, ensuring alignment with community priorities.
- Open Access
- 6 August 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-16
Assessing the socio-economic burden of inherited and inflammatory neuromuscular diseases (BIND study): a study protocol
Introduction: Neuromuscular diseases (NMDs) are rare multisystem, genetic or acquired disorders causing weakness and/or sensory loss. It is essential for governments, insurance providers, and broader society to have a better understanding of the burden of illness of NMDs. Our goal is to assess the social and economic burden of Canadians living with NMDs, encompassing schooling and education achievement, health-related quality-of-life, and labour force participation and productivity. Methods and analysis: We will conduct a national, cross-sectional survey of individuals living with a NMD and their caregivers who are members of Muscular Dystrophy Canada and/or are patients within our national network of neuromuscular clinics. Surveys can be completed online or via telephone. The specific sub-sections of the questionnaire will differ based on respondent’s profile, whether they are 1) a minor living with a NMD, 2) an adult living with a NMD, 3) an adult who is a caregiver for someone living with a NMD, or 4) an adult who both lives with a NMD and is a caregiver for someone with a NMD. We will use descriptive statistics to describe distributions and ranges of the social and economic measures. Pearson correlations for continuous data and Spearman rho for rank data will be used to detect the strength of association of socio-demographic factors, disease characteristics, and social and economic impacts of NMDs. Ethics and dissemination: The study protocol has been approved by the Ottawa Health Science Network Research Ethics Board (Protocol ID # 20210601-01H). This study will provide the overall impact of NMD on costs and health-related quality of life, disseminated via a series of manuscripts which will include both between- and within-NMD/NMD subtype comparisons. The data obtained will guide governmental policy development and inform patient organisation programs to deliver more effective supports to individuals and families affected by NMDs.
- 6 August 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-16
Open AccessAssessing the socio-economic burden of inherited and inflammatory neuromuscular diseases (BIND study): a study protocol
Introduction: Neuromuscular diseases (NMDs) are rare multisystem, genetic or acquired disorders causing weakness and/or sensory loss. It is essential for governments, insurance providers, and broader society to have a better understanding of the burden of illness of NMDs. Our goal is to assess the social and economic burden of Canadians living with NMDs, encompassing schooling and education achievement, health-related quality-of-life, and labour force participation and productivity. Methods and analysis: We will conduct a national, cross-sectional survey of individuals living with a NMD and their caregivers who are members of Muscular Dystrophy Canada and/or are patients within our national network of neuromuscular clinics. Surveys can be completed online or via telephone. The specific sub-sections of the questionnaire will differ based on respondent’s profile, whether they are 1) a minor living with a NMD, 2) an adult living with a NMD, 3) an adult who is a caregiver for someone living with a NMD, or 4) an adult who both lives with a NMD and is a caregiver for someone with a NMD. We will use descriptive statistics to describe distributions and ranges of the social and economic measures. Pearson correlations for continuous data and Spearman rho for rank data will be used to detect the strength of association of socio-demographic factors, disease characteristics, and social and economic impacts of NMDs. Ethics and dissemination: The study protocol has been approved by the Ottawa Health Science Network Research Ethics Board (Protocol ID # 20210601-01H). This study will provide the overall impact of NMD on costs and health-related quality of life, disseminated via a series of manuscripts which will include both between- and within-NMD/NMD subtype comparisons. The data obtained will guide governmental policy development and inform patient organisation programs to deliver more effective supports to individuals and families affected by NMDs.
- Open Access
- 5 April 2023
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 21 (April) , 1-9
Cost-effectiveness analysis of the SMART quit clinic program in smokers with cardiovascular disease in Thailand
Introduction: The SMART Quit Clinic Program (FAHSAI Clinic) has been implemented in Thailand since 2010; however, it remains unclear whether the benefits gained from this program justify its costs. We assessed its cost-effectiveness compared to usual care in a population of Thai smokers with...
- 5 April 2023
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 21 (April) , 1-9
Open AccessCost-effectiveness analysis of the SMART quit clinic program in smokers with cardiovascular disease in Thailand
Introduction: The SMART Quit Clinic Program (FAHSAI Clinic) has been implemented in Thailand since 2010; however, it remains unclear whether the benefits gained from this program justify its costs. We assessed its cost-effectiveness compared to usual care in a population of Thai smokers with...